<?xml version="1.0" encoding="UTF-8"?>
<p>Interest by foundations and philanthropists in advanced development of vaccines against future epidemics has been stimulated by the challenges posed both by the Ebola and Zika viruses. Obviously, commercial interest in investing in such development is limited by the poverty of citizens in the countries where they first strike. There is also a problem in generating a perception of need for a drug to treat a threat which, in the words of Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Disease, “hasn’t happened yet” [
 <xref rid="B3-ijerph-14-01304" ref-type="bibr">3</xref>].
</p>
